MDA
3,4-methylenedioxyamphetamine
Viewing r1 — Apr 24, 2026 — CURRENT
Back to HistoryInteractions, related substances, and reports reflect the current entry and are not shown for historical revisions.
MDA (3,4-methylenedioxyamphetamine) — Sass, Sally, Love Drug — is a synthetic empathogen of the substituted amphetamine class. It is the parent compound of MDMA, distinguished by direct psychedelic activity. MDA is a triple monoamine releasing agent and 5-HT₂A receptor agonist, producing its effects by flooding serotonin, dopamine, and norepinephrine into the synapse while directly activating psychedelic receptors.[1]
Psychedex is in open beta. We are still fine-tuning the generation and review process. Please double-check sources.
First synthesized in 1910 by Mannish and Jacobson,[2] MDA was investigated as an antidepressant and appetite suppressant through the 1950s before entering recreational circulation as the "Love Drug" in the 1960s. David Nichols cited it as a conceptual anchor when coining the term "entactogen" in 1986.[3] It was scheduled in 1970[4] and remains prohibited in most jurisdictions, with no approved therapeutic use.
Subjective effects include empathogenic warmth, geometric visual patterns, stimulation, wakefulness, and emotional openness. The experience layers entactogenic closeness over genuine closed-eye hallucinations and full-body stimulation — a combination distinguishing MDA from both pure psychedelics and pure empathogens.[5] Anxiety, elevated fear, and cardiovascular strain are characteristic unsought effects.[6]
No physical dependence has been documented, but MDA is more neurotoxic than MDMA on a per-dose basis, selectively destroying serotonin nerve terminals through toxic metabolites formed in the liver.[7][8] The primary risk is cumulative serotonergic damage amplified by heat — small increases in ambient temperature dramatically worsen neurotoxicity,[9] making hot environments the most dangerous contextual factor. A 2026 head-to-head trial provides the strongest human data,[6] but human neurotoxicity thresholds, oral bioavailability, and therapeutic index remain uncharacterized.
History[edit]
Discovery
MDA was first synthesized in 1910 by the German chemists G. Mannish and W. Jacobson,[2] years before its better-known derivative MDMA. The compound sat dormant until 1939, when animal studies revealed stimulant activity and convulsions at high doses.[2] First human trials followed in 1941, initially exploring applications in Parkinson's disease.[2]
Clinical and cultural significance
Between 1949 and 1957, Smith, Kline, and French tested MDA in over 500 subjects as an antidepressant and appetite suppressant, briefly marketing it as "Amphedoxamine".[2] Further patents covered use as a cough suppressant, anxiolytic, and anorectic — none achieved lasting clinical adoption.[2] In 1986, David Nichols formalized the pharmacological class MDA had helped define, coining the term "entactogen" — literally "touching within" — to describe compounds producing empathogenic effects distinct from both classical psychedelics and stimulants.[3]
Prohibition and modern use
Recreational use surfaced in 1963–1964, and MDA earned the street name "Love Drug" for its combination of empathogenic warmth and mild hallucinogenic effects.[2] In 1970, MDA became a Schedule I controlled substance in the United States — its scheduling directly accelerated the rise of MDMA, which remained legal for another fifteen years.[4] No clinical trials have investigated MDA as a primary therapeutic agent; the most significant modern data comes from a 2026 head-to-head comparison with MDMA at the University Hospital Basel.[6]
The name "Sass" — MDA's most common contemporary street name — derives from sassafras oil, the natural source of safrole from which MDA has historically been synthesized in clandestine laboratories.[10] "Sally" follows as a feminized variant. The older epithet "Love Drug" reflects the compound's reputation in 1960s counterculture, where its empathogenic warmth was its defining social identity — a role later inherited by MDMA.
Chemistry[edit]
Structural class
MDA belongs to the substituted amphetamine family and is the parent compound of the methylenedioxy amphetamine series (MDxx compounds). Its defining feature is a 3,4-methylenedioxy ring — a fused dioxole group bridging two positions on the phenyl ring — attached to the amphetamine backbone. MDA is the N-desmethyl structural analog of MDMA: the two compounds differ by a single methyl group on the nitrogen atom.
This one-atom distinction has outsized pharmacological consequences. MDA retains direct 5-HT₂A receptor agonism and stronger dopamine release, while MDMA is a more selective entactogen with minimal psychedelic properties. Other members of the MDxx series include MDEA, MDOH, and MBDB.
Molecular properties
| Molecular formula | C₁₀H₁₃NO₂ |
| Molecular weight | 179.22 g/mol |
The molecule consists of a benzodioxole (methylenedioxyphenyl) ring system connected via a methylene bridge to a propan-2-amine chain. The primary amine nitrogen is unsubstituted — distinguishing MDA from its N-methylated congener MDMA and N-ethylated congener MDEA.
Stereochemistry
MDA has one chirality center, yielding two mirror-image forms: S-(+)-MDA and R-(−)-MDA. The racemic mixture (equal mixture) is the form encountered in recreational settings and used in most studies. The S-(+)-isomer carries greater stimulant potency,[11] consistent with the general pattern among amphetamine derivatives.
When MDA is formed as a metabolite of racemic MDMA, the body preferentially produces the (R)-form.[12]
Physical properties
MDA free base is a colorless to pale yellow oil. The hydrochloride salt — the most commonly encountered form — is a white to off-white crystalline powder soluble in water. The methylenedioxy ring is also present in safrole, a natural product from which MDA has historically been synthesized in clandestine settings.[10]
Pharmacology[edit]
Mechanism of action
MDA works by entering the serotonin, dopamine, and norepinephrine transporters as a false substrate and reversing their direction, flooding all three monoamines into the synapse simultaneously. Among the three transporters, MDA inhibits the norepinephrine transporter most potently[1] and releases more dopamine than MDMA from brain tissue,[13] explaining its more pronounced stimulant character.
The critical distinction from MDMA is that MDA also directly activates the 5-HT₂A receptor[1] — the same receptor targeted by classical psychedelics like LSD and psilocybin mushrooms. This dual mechanism — monoamine release plus direct psychedelic receptor activation — is confirmed by drug discrimination studies showing MDA substitutes for both LSD and amphetamine in trained animals,[14] while MDMA is primarily amphetamine-like. The MDMA discriminative cue generalizes completely to MDA, confirming shared entactogen-class properties.[11]
Pharmacokinetics
Following oral administration of 92 mg in healthy volunteers, effects begin at approximately 42 minutes, peak at around 2 hours, and last a total of approximately 6 hours.[6] The plasma half-life is 8.4 hours — slightly longer than MDMA's 7.3 hours under identical conditions.[6] Oral bioavailability has not been directly measured.
MDA is metabolized in the liver primarily by CYP2D6, which converts it to alpha-methyldopamine — a catechol metabolite of major toxicological significance.[15][16] People who metabolize CYP2D6 substrates slowly (poor metabolizers), or who take CYP2D6 inhibitors such as fluoxetine or paroxetine, will experience elevated MDA blood levels and increased toxicity risk.[17]
Like MDMA, MDA likely inhibits its own metabolism, meaning that doubling the dose can more than double blood concentrations — a nonlinear relationship that makes dose escalation disproportionately dangerous.
Neurotoxic metabolites
Alpha-methyldopamine, MDA's primary liver metabolite, is itself neurotoxic. It oxidizes and conjugates with glutathione to form thioether compounds that cross into the brain, cause acute monoamine release, and ultimately destroy serotonin nerve terminals.[8][18] MDA injected directly into the brain does not cause this damage — peripheral liver metabolism to these reactive intermediates is required.[8]
The glutathione-thioether conjugates are the most toxic species in the pathway.[18]
MDA as an MDMA metabolite
MDMA is converted to MDA in the body at a plasma ratio of approximately 3–5% (MDA:MDMA).[19][12] All MDMA users are simultaneously exposed to MDA and its neurotoxic metabolites. The body preferentially produces the (R)-MDA enantiomer from racemic mixture MDMA.[12]
Neuroscience[edit]
Where it acts
MDA engages three neural systems simultaneously. Its serotonin release reduces amygdala threat reactivity and enhances prefrontal-amygdala connectivity — the circuits underlying empathogenic warmth, paralleling documented MDMA effects.[13] Its direct 5-HT₂A agonism[1][20] disrupts thalamocortical gating and default mode network integrity, producing the closed-eye geometry and formed imagery documented in controlled studies.[5]
Pronounced dopamine[13] and norepinephrine[1] release activate the mesolimbic mesolimbic pathway and the locus coeruleus arousal system, driving the stimulant profile confirmed as stronger than MDMA's in human trials.[6]
Why it matters
MDA is a natural pharmacological test case for what happens when entactogenic and psychedelic mechanisms co-occur. Under the REBUS (Relaxed Beliefs Under Psychedelics) framework, 5-HT₂A agonists loosen the brain's top-down expectations, allowing raw sensory signals greater influence on conscious experience. MDA's documented disruption of contour integration and object recognition[5] fits this model. The simultaneous monoamine-driven emotional intensification may amplify the felt significance of the resulting perceptual shifts.
Both serotonergic psychedelics and MDMA promote neuroplasticity through overlapping but distinct pathways. MDA, engaging both simultaneously, may have enhanced plasticity-promoting potential — but this has not been directly tested.
No neuroimaging studies of MDA in humans have been published. Key unknowns include whether the dual mechanism produces greater neuroplasticity than either MDMA or classical psychedelics alone, what 5-HT₂A receptor occupancy looks like at recreational doses, and whether MDA's greater preclinical neurotoxicity translates to measurable serotonin system damage in human users.
Subjective Effects[edit]
MDA produces an experience in which stimulant energy, empathogenic warmth, and psychedelic perception co-occur rather than alternating. At lower doses, the entactogenic and stimulant layers dominate; at common doses and above, direct 5-HT₂A agonism introduces genuine closed-eye hallucinations — geometry, formed imagery, and complex scenes — that become a defining feature.[5] Set and setting modulate the balance between prosocial openness and anxiety more sharply than with MDMA, as fear and dysphoria emerge even in controlled environments.[6]
MDA sits between MDMA and classical psychedelics like LSD. It shares MDMA's emotional warmth and physical drive but adds perceptual depth — particularly visual — that MDMA lacks. The stimulant component is stronger than either, and the overall experience is longer and more physically taxing.
Effect Grid
At common doses (60–100 mg oral), all three pharmacological dimensions are fully expressed. Entactogenic effects — empathy enhancement, emotional openness, increased desire for social connection — are prominent. Stimulation is marked: wakefulness, thought acceleration, and physical energy. The psychedelic component produces color enhancement, visual brightening, and, in approximately 50% of individuals, closed-eye visions including geometric patterns and formed imagery.
Bruxism (jaw clenching), pupil dilation, sweating, and elevated heart rate are typical. Temperature dysregulation becomes clinically relevant — overheating risk increases, especially in warm environments or during physical exertion.
Total duration is approximately 5–7 hours, with peak effects around 1.5–3 hours post-ingestion. Sleep is unlikely for 8+ hours. The experience demands a full evening's commitment.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Visual haze / noise · Tracers · Sleep-transition hallucinations · After-images · Brightness alteration · Color alteration · Geometry · Light sensitivity · Sound sensitivity · Symmetrical texture repetition · Auditory distortion · Depth perception distortion · Spatial disorientation · Synesthesia · Visual breathing · Visual drifting · Peripheral misidentification · Environmental patterning · Peripheral vision distortion · Perspective distortion · Proprioceptive distortion · Visual diffraction · Visual morphing · Internal hallucinations · Object transformations · External hallucinations
Brightness alteration · Color alteration · Geometry · Light sensitivity · Sound sensitivity · Symmetrical texture repetition · Auditory distortion · Depth perception distortion · Spatial disorientation · Synesthesia · Visual breathing · Visual drifting · Peripheral misidentification · Environmental patterning · Peripheral vision distortion · Perspective distortion · Proprioceptive distortion · Visual diffraction · Visual morphing · Internal hallucinations · Object transformations · External hallucinations
Pupil dilation · Insomnia · Excessive sweating · Dehydration sensation · Body high · Dry mouth · Physical fatigue · Spontaneous body sensations · Bruxism · Bodily lightness · Tactile euphoria · Tingling / electric sensations · Sexual arousal enhancement · Muscle tension · Heart rate perception changes · Motor control impairment · Nausea · Nystagmus (eye wobbles) · Restlessness · Vasoconstriction · Vibrations / buzzing · Brain zaps · Dizziness · Sexual arousal suppression · Increased urination · Body schema distortion · Yawning · Motor control enhancement · Seizure threshold reduction
Dehydration sensation · Body high · Dry mouth · Physical fatigue · Spontaneous body sensations · Bruxism · Bodily lightness · Tactile euphoria · Tingling / electric sensations · Sexual arousal enhancement · Muscle tension · Heart rate perception changes · Nausea · Nystagmus (eye wobbles) · Restlessness · Vasoconstriction · Vibrations / buzzing · Brain zaps · Dizziness · Sexual arousal suppression · Increased urination · Body schema distortion · Yawning · Motor control enhancement · Seizure threshold reduction
Openness enhancement · Immersion enhancement · Thought acceleration · Novelty enhancement · Motivation suppression · Introspection enhancement · Pattern recognition enhancement · Creativity enhancement · Motivation enhancement · Humor enhancement · Cognitive impairment · Suggestibility enhancement · Thought connectivity · Focus enhancement · Thought disorganization · Thought deceleration · Confusion
Novelty enhancement · Motivation suppression · Introspection enhancement · Pattern recognition enhancement · Creativity enhancement · Motivation enhancement · Humor enhancement · Cognitive impairment · Thought connectivity · Focus enhancement · Thought disorganization · Thought deceleration · Confusion
Anhedonia · Anxiety suppression · Irritability · Catharsis · Emotional lability · Anxiety · Dysphoria · Suicidal ideation
Catharsis · Emotional lability · Anxiety · Dysphoria
Emotional susceptibility · Communication enhancement · Flow state · Derealization · Craving · Boundary dissolution
Craving · Boundary dissolution
Timeline
First alerts emerge 30-60 minutes after ingestion: a subtle shift in mood, mild warmth in the chest, and faint stimulation. Most individuals notice the transition clearly by 40 minutes.
Effects build steadily over 30-60 minutes. Empathogenic warmth, increasing stimulation, and the first visual brightening develop in parallel. Nausea or stomach unease is possible during this phase.
Full expression of the MDA triad: entactogenic openness, pronounced stimulation, and psychedelic visual effects including closed-eye visions in susceptible individuals. Emotional intensity is maximal. Bruxism, pupil dilation, and sweating are prominent.
Intensity gradually recedes from peak levels but remains clearly psychoactive. Stimulation persists while entactogenic and visual effects soften. Conversation and social engagement often increase as the overwhelming quality diminishes.
Effects taper over 1-1. 5 hours. Stimulation fades last, leaving residual wakefulness and mild mood elevation.
Residual wakefulness and mild mood changes persist for 2-4 hours beyond the main experience, consistent with MDA's 8. 4-hour plasma half-life exceeding its 6. 1-hour subjective duration.
Safety[edit]
- Acute toxicity
- Moderate
- Chronic toxicity
- Moderate
- Withdrawal
- None
- Tolerance buildup
- rapid
- Tolerance reset
- 7 days
- Physical
- Negligible
- Psychological
- Low
- Compulsive redosing
- Low
- Dose escalation
- Low
- Cross-tol.
- MDMA · 5-HT psych. · amphetamines
Toxicity
Serotonergic neurotoxicity
MDA causes greater destruction of serotonin nerve terminals than MDMA at equivalent doses.[7] In animal models, repeated dosing selectively ablates serotonin wiring throughout the forebrain while leaving other neurotransmitter systems intact. The damage is not caused by MDA itself but by toxic metabolites — thioether compounds formed when the liver processes MDA through CYP2D6.[8][18] MDA injected directly into the brain does not produce neurotoxicity; peripheral metabolism is required.[8]
Temperature is a critical amplifier. Small increases in ambient temperature (as little as 2°C) dramatically worsen serotonin neurotoxicity in animal models.[9] Neurotoxicity was not observed at cool ambient temperatures but correlated strongly with overheating at warmer temperatures. Hot environments — dance floors, clubs, festivals — substantially amplify the neurotoxic risk of MDA use.
All direct neurotoxicity data come from animal models. No controlled human studies have measured serotonin marker changes following MDA administration.
Cardiovascular toxicity
MDA is the most potent blood pressure-raising agent among the MDxx compounds, acting through direct stimulation of alpha-1 adrenoceptors.[22] In animal studies, MDA produced the most marked rise in blood pressure compared to MDMA and MDEA, accompanied by reflex heart rate slowing and subsequent overheating.[22]
Acute lethality
No human lethal dose or therapeutic index has been established. The lethal dose in dogs is approximately 8 mg/kg intravenously,[23] with death preceded by overheating, rapid heart rate, and high blood pressure progressing to cardiovascular collapse.[24] Human fatalities involving amphetamine-class compounds most commonly resulted from heart and lung failure, overheating, and physical trauma, with most victims male and under 25.[25]
Psychological risks
A controlled trial found that MDA produced significantly greater fear and "bad drug effects" than MDMA at comparable doses.[6] This elevated anxiety potential — likely driven by the combination of psychedelic receptor activation and strong epinephrine-like effects — represents a meaningful psychological risk.
MDA's 5-HT₂A agonism places it in the same risk category as classical psychedelics for triggering acute psychotic episodes in predisposed individuals.inferred No MDA-specific data on substance-induced psychosis prevalence exist. Hallucinogen persisting perception disorder (HPPD) is theoretically possible given MDA's confirmed visual effects, but no MDA-specific cases have been reported.
Tolerance and dependence
No MDA-specific tolerance or dependence studies have been published. The MDxx class generally produces rapid acute tolerance to empathogenic effects, driven by serotonin depletion after massive release. Cross-tolerance with serotonergic psychedelics and other stimulants is pharmacologically plausible but unconfirmed.
MDA's greater stimulant burden compared to MDMA[6] suggests that compulsive use patterns are possible through dopamine-driven reinforcement. The elevated fear and discomfort may paradoxically limit compulsive redosing. Physical dependence and withdrawal have not been characterized.
Drug interactions
Serotonergic agents
Combination with any drug that raises serotonin levels — MAOIs, SSRIs, SNRIs, serotonergic painkillers, triptans, St. John's wort — creates risk for serotonin syndrome. Severe cases manifest as dangerous overheating, muscle rigidity, uncontrollable muscle jerking, and organ failure.[26]
MAOIs: Monoamine oxidase inhibitors prevent breakdown of the serotonin, dopamine, and norepinephrine that MDA releases. The combination can cause lethal serotonin syndrome and dangerous blood pressure spikes. This interaction is potentially fatal.
Tramadol: tramadol blocks serotonin and norepinephrine reuptake,[27] creating conditions for severe serotonin toxicity when combined with MDA's massive serotonin release.safety citation needed
MDMA
Combined use of MDA and MDMA produces additive serotonergic effects. Both are serotonin releasers; co-administration increases overheating risk, cardiovascular stress, and serotonin toxicity risk.
CYP2D6 inhibitors
Fluoxetine, paroxetine, quinidine, bupropion, and other CYP2D6 inhibitors slow MDA metabolism, substantially increasing blood levels and toxicity risk.[17]
Norepinephrine reuptake inhibitors
Norepinephrine reuptake inhibitors such as reboxetine reduce cardiovascular and stimulant effects by blocking norepinephrine release at the transporter.[28] This interaction is antagonistic — it may blunt both desired stimulant effects and dangerous cardiovascular effects.
Contraindications
Heart conditions and high blood pressure: MDA is the most potent blood pressure-raising agent in the MDxx series.[22] Pre-existing cardiovascular disease, uncontrolled high blood pressure, and structural heart abnormalities are absolute contraindications.
Psychotic disorders and bipolar disorder: MDA's psychedelic receptor activity carries the same risk of precipitating psychotic episodes as classical psychedelics. Personal or family history of psychosis, schizophrenia, or bipolar disorder I is an absolute contraindication.inferred
Liver impairment: MDA metabolism depends on liver enzymes.[15] Impaired liver function reduces clearance, increasing blood levels and extending duration and toxicity risk.
MAOIs: Absolute contraindication. Combination creates risk of fatal serotonin syndrome and dangerous blood pressure crisis.
SSRIs/SNRIs: Relative contraindication. SSRIs blunt empathogenic effects by competing at the SERT while retaining residual serotonin toxicity risk.
Tramadol and serotonergic painkillers: Absolute contraindication. The mechanistic basis for lethal serotonin toxicity is established.[27][26]
Pregnancy and breastfeeding: No reproductive toxicity data specific to MDA exist. Given its potent stimulant and serotonergic activity, use during pregnancy is absolutely contraindicated.inferred
Harm Reduction[edit]
Forms & Identification
MDA is most commonly encountered as the hydrochloride salt — a white to off-white powder or crystalline substance that may also be pressed into tablets. It is frequently sold as "Sass" or "Molly" and is routinely confused with or substituted for MDMA, making reagent testing essential before every use. The structured module above shows expected reagent responses; the critical point is that MDA and MDMA produce different color reactions with Marquis and Simon's reagents, allowing differentiation.
Because MDA's neurotoxic and cardiovascular risks exceed MDMA's, knowing which compound is actually present changes the risk calculation meaningfully. Purity varies widely in unregulated supply. MDA's dose-response curve is steep and its metabolism is nonlinear — small increases in actual dose can produce disproportionate increases in blood concentration.
Guidelines
- Test every dose with at least Marquis and Simon's reagents to confirm substance identity and differentiate from MDMA
- Start low. MDA's nonlinear metabolism means doubling the dose more than doubles blood levels. First-time users should begin at the lower end of the common dose range
- Control temperature. Stay in cool environments. Avoid crowded, hot venues. Take breaks from physical activity. Overheating is the single most modifiable risk factor for serotonergic neurotoxicity[9]
- Hydrate steadily but avoid overhydration — sip water regularly rather than drinking large volumes at once
- Have a sitter if the psychedelic component is unfamiliar. MDA's hallucinogenic effects can be disorienting and anxiety-provoking
- Do not redose. Acute tolerance develops quickly, and redosing increases neurotoxicity risk without proportionally extending the desired experience
- Space use widely. The MDxx class requires extended intervals between uses for serotonin system recovery. Minimum recommended spacing is 6–8 weeks, though longer is safer
Set & Setting
MDA's dual empathogenic-psychedelic character makes psychological preparation and environment more consequential than with MDMA alone. The 2026 controlled trial documented elevated fear and bad drug effects even in clinical settings,[6] confirming that anxiety can surface regardless of preparation. A calm, temperature-controlled environment is especially important: ambient heat dramatically amplifies neurotoxicity.[9]
The psychedelic component means genuine hallucinations — closed-eye geometry, formed images, complex scenes[5] — can occur at common doses and above. Individuals without prior psychedelic experience should be aware that visual and cognitive distortions are expected, not signs of a medical emergency.
Aftercare & integration. The days following MDA use may include low mood, fatigue, irritability, and difficulty concentrating — a comedown driven by temporary serotonin depletion. These effects typically resolve within 3–5 days. Adequate sleep, nutrition, and light physical activity support recovery. Avoid other serotonergic substances during this period.
MDA's psychedelic component can produce meaningful or challenging psychological material — vivid imagery, emotional insights, or distressing experiences. Journaling, conversation with trusted people, or a session with a psychedelic-informed therapist can help process difficult content. Persistent anxiety, depersonalization, or visual disturbances lasting more than two weeks warrant professional evaluation.
Recovery & Support
While MDA does not produce physical dependence, patterns of repeated use can develop — particularly where the stimulant and empathogenic effects serve as emotional coping tools. Escalating frequency despite awareness of neurotoxic risk is a warning sign. Support options include psychedelic integration circles, harm reduction organizations (DanceSafe, The Loop), SMART Recovery, and substance use counselors familiar with club drugs and psychedelics.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency:
An MDA experience can be uncomfortable without being dangerous. Signs that require immediate help: chest pain or pressure, seizure, loss of consciousness, body temperature hot to the touch through clothing, rigid or jerking muscles, confusion severe enough to prevent communication, or uncontrollable panic with self-harm risk.
Immediate steps:
- 1. Call emergency services if any of the above signs are present
- 2. Move the person to a cool, quiet area
- 3. Remove excess clothing and apply cool water to skin if overheating is suspected
- 4. Place unconscious but breathing individuals in the recovery position (on their side)
- 5. Do not restrain unless there is immediate danger of self-harm
- 6. Do not induce vomiting
What to tell the dispatcher:
State the substance (MDA or "an MDMA-like stimulant"), the amount if known, the time taken, and current symptoms — particularly body temperature, consciousness level, and any seizure activity. Good Samaritan laws in many jurisdictions protect people who call for help during a drug emergency.
Legal Status[edit]
MDA is internationally controlled under Schedule I of the United Nations Convention on Psychotropic Substances (1971). It was among the first entactogenic compounds to be specifically scheduled, preceding the scheduling of MDMA by over a decade.
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Schedule I (Controlled Substances Act) | Classified in 1970; no accepted medical use, high abuse potential[4] |
| United Kingdom | Class A (Misuse of Drugs Act 1971) | Maximum penalty for supply: life imprisonment; possession: 7 years[2] |
| Canada | Controlled (CDSA)citation needed | Classification requires verification; secondary sources cite Schedule III but this may be erroneous |
| Australia | Schedule 9 (Standard for the Uniform Scheduling of Medicines and Poisons) | Prohibited substance; no therapeutic use recognized[2] |
| International | Schedule I (UN Convention on Psychotropic Substances, 1971) | Parties required to prohibit use except for scientific and very limited medical purposes |
Analog act considerations
In the United States, MDA itself is specifically scheduled and does not require invocation of the Federal Analogue Act. Novel MDA analogs — fluorinated or ring-substituted derivatives not specifically listed — may fall under the Analogue Act if sold for human consumption and substantially similar in structure or effect. The lysine prodrug of MDA (Lys-MDA) studied in the 2026 Basel trial[6] converts to MDA in the body and would likely be treated as an MDA analog under federal law absent specific scheduling.
references
- [1]
- [2]
- [3] ^abNichols DE (1986) Differences between the mechanism of action of MDMA, MBDB, and the classic hallucinogens. Identification of a new therapeutic class: entactogens — Journal of Psychoactive Drugs PMID:2880944
- [4]
- [5]
- [6]